Literature DB >> 21987611

IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.

Mauricio Venegas1, Rodrigo A Villanueva, Katherine González, Javier Brahm.   

Abstract

AIM: To analyze the association of three IL28B single nucleotide polymorphisms with response to therapy in Chilean patients infected with hepatitis C virus (HCV).
METHODS: We studied two groups of patients with chronic HCV infection (genotype 1), under standard combined treatment with pegylated interferon plus ribavirin. One group consisted of 50 patients with sustained virological response, whereas the second group consisted of 49 null responders. In order to analyze the IL28B single nucleotide polymorphisms rs12979860, rs12980275 and rs8099917, samples were used for polymerase chain reaction amplification, and the genotyping was performed by restriction fragment length polymorphism.
RESULTS: The IL28B rs12979860 CC, rs12980275 AA and rs8099917 TT genotypes were much more frequently found in patients with sustained virological response compared to null responders (38%, 44% and 50% vs 2%, 8.2% and 8.2%, respectively). These differences were highly significant in all three cases (P < 0.0001).
CONCLUSION: The three IL28B polymorphisms studied are strongly associated with sustained virological response to therapy in Chilean patients with chronic HCV (genotype 1).

Entities:  

Keywords:  Chile; Hepatitis C virus; IL28B; Pegylated interferon; Ribavirin

Mesh:

Substances:

Year:  2011        PMID: 21987611      PMCID: PMC3180021          DOI: 10.3748/wjg.v17.i31.3636

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  8 in total

Review 1.  IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.

Authors:  Paul J Clark; Alex J Thompson; John G McHutchison
Journal:  Am J Gastroenterol       Date:  2010-10-05       Impact factor: 10.864

2.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

Review 3.  Natural history of chronic hepatitis C.

Authors:  Leonard B Seeff
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 4.  Epidemiology of hepatitis C virus infection.

Authors:  Miriam J Alter
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

5.  [Prevalence and genotypes of hepatitis C virus in blood donors and in patients with chronic liver disease and hepatocarcinoma in a Chilean population].

Authors:  G Muñoz; M Velasco; V Thiers; C Hurtado; J Brahm; M Larrondo-Lillo; A Guglielmetti; G Smok; C Brechot; E Lamas
Journal:  Rev Med Chil       Date:  1998-09       Impact factor: 0.553

6.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

7.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

  8 in total
  17 in total

Review 1.  MiR-122 in hepatitis B virus and hepatitis C virus dual infection.

Authors:  Kyoungsub Song; Chang Han; Srikanta Dash; Luis A Balart; Tong Wu
Journal:  World J Hepatol       Date:  2015-03-27

2.  EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C.

Authors:  M Asnavandi; M Zargar; F Vaziri; F R Jamnani; S Gharibzadeh; A Fateh; S D Siadat
Journal:  Genes Immun       Date:  2017-07-13       Impact factor: 2.676

3.  Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients.

Authors:  Abdolvahab Alborzi; Tayebeh Hashempour; Javad Moayedi; Zahra Musavi; Gholamreza Pouladfar; Shahin Merat
Journal:  Med Microbiol Immunol       Date:  2017-02-18       Impact factor: 3.402

4.  Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?

Authors:  Raquel Francine Liermann Garcia; Simone Moreira; Ana Lucia de Araújo Ramos; Leslie Ecker Ferreira; Angelo Alves de Mattos; Cristiane Valle Tovo; Lysandro Alsina Nader; Juliene Antonio Ramos; Edson Rondinelli; Arnaldo de Jesus Dominici; Christian Evangelista Garcia; Mauro de Souza Leite Pinho; Carlos Eduardo Brandão-Mello; Cristiane Alves Villela-Nogueira; Paulo Henrique Condeixa de França
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 5.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

Review 6.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

7.  Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis.

Authors:  Hamid Heidarian Miri; Pooria Fazeli; Mohammad Ali-Hassanzadeh; Peyman Bemani; Dieter Kabelitz; Kurosh Kalantar
Journal:  Arch Virol       Date:  2021-07-03       Impact factor: 2.574

8.  Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

Authors:  María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino
Journal:  BMC Med       Date:  2013-01-08       Impact factor: 8.775

9.  A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-κB-mediated gene transcription.

Authors:  Sreedhar Chinnaswamy; Snehajyoti Chatterjee; Ramachandran Boopathi; Shuvolina Mukherjee; Samsiddhi Bhattacharjee; Tapas K Kundu
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

10.  SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treatment.

Authors:  Simone Regina Souza da Silva Conde; Julius Caesar Mendes Soares Monteiro; Bruna Tereza Silva Dos Santos; Nathália Karla Fonseca Filgueiras; Pedro Alves de Almeida Lins; Felipe Bonfim Freitas; Ednelza da Silva Graça; Sâmia Demachki; Marialva Tereza Ferreira de Araújo; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  Biomed Res Int       Date:  2014-02-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.